Company Overview

Lifeward Ltd. is a medical technology company that develops, manufactures, and markets advanced assistive devices designed to improve mobility, rehabilitation, and quality of life for individuals with physical disabilities. The company operates within the medical devices, rehabilitation technology, and assistive robotics industries, serving clinical, rehabilitation, and home-use markets. Its core focus is on restoring or enhancing functional movement for people with spinal cord injuries, stroke-related impairments, and other neuromuscular conditions.

The company’s primary revenue drivers are robotic exoskeleton systems, balance and fall-prevention technologies, and related service and support offerings. Lifeward serves rehabilitation hospitals, outpatient clinics, veterans’ healthcare systems, and individual users, with a particular emphasis on patients with lower-limb disabilities. The company positions itself as a pioneer in wearable robotic mobility solutions, leveraging clinically validated technology and regulatory clearances in multiple jurisdictions. Founded in 2001 under the name ReWalk Robotics Ltd., the company rebranded to Lifeward Ltd. in 2023 to reflect a broader mission beyond exoskeletons and a more diversified product portfolio.

Business Operations

Lifeward’s operations are organized around several core product lines that collectively generate revenue through device sales, leasing arrangements, training, and maintenance services. The company’s flagship offering is the ReWalk Personal Exoskeleton, a wearable robotic device designed to enable upright walking for individuals with spinal cord injury. Additional products include ReWalk Rehabilitation, used in clinical settings, ReStore Soft Exo-Suit for post-stroke gait rehabilitation, and MyoCycle, a functional electrical stimulation cycling system for neurological rehabilitation.

The company operates both domestically and internationally, with sales activities in North America, Europe, and select Asia-Pacific markets. Lifeward controls proprietary robotics, sensor, and control technologies and maintains regulatory approvals, including U.S. FDA clearances and CE marking in Europe, which represent significant barriers to entry. Its operations include manufacturing oversight, clinical training programs, and post-sale technical support. Data inconclusive based on available public sources regarding material joint ventures; however, the company has historically relied on distributor relationships and clinical partnerships to expand market access.

Strategic Position & Investments

Lifeward’s strategic direction centers on expanding adoption of its existing mobility solutions while diversifying into adjacent rehabilitation and assistive technologies. Growth initiatives include increasing penetration in veterans’ healthcare systems, expanding reimbursement coverage with public and private payers, and broadening clinical evidence to support wider prescription and insurance acceptance. The company has also emphasized cost management and operational efficiency following its rebranding and restructuring efforts.

Notable investments include the acquisition of AlterG, Inc., a company specializing in anti-gravity treadmill technology used for rehabilitation and athletic training, which significantly broadened Lifeward’s product portfolio and revenue base. Through this acquisition, Lifeward gained exposure to orthopedic, sports medicine, and physical therapy markets. The company continues to evaluate emerging rehabilitation technologies, including soft robotics and digital gait analytics, though specific future investments beyond publicly disclosed transactions are inconclusive based on available public sources.

Geographic Footprint

Lifeward is headquartered in Israel, with significant operational and commercial presence in the United States, which represents its largest market by revenue. The company maintains offices, training centers, or distribution networks across Europe, including Germany and the United Kingdom, supporting both direct sales and distributor-led models. Its international footprint enables access to government-funded healthcare systems as well as private rehabilitation providers.

Beyond its primary markets, Lifeward has a limited but growing presence in Asia-Pacific, primarily through distributors and strategic partners. International operations are influenced by varying reimbursement regimes, regulatory pathways, and clinical adoption rates, which the company addresses through localized market strategies and regulatory compliance efforts.

Leadership & Governance

Lifeward is led by an executive team with experience in medical devices, rehabilitation technology, and global commercialization. While the company does not emphasize a single founder-led narrative in its current governance structure, its leadership philosophy focuses on clinical validation, patient-centered design, and disciplined capital allocation to support sustainable growth.

Key executives include:

• Larry Jasinski – Chief Executive Officer
• Mark Klausner – Chief Financial Officer
• Ronen Shemtov – Chief Technology Officer
• Erik Mickelson – Chief Commercial Officer

The company operates under a board-governed structure consistent with publicly traded medical device firms, with oversight of strategy, risk management, and regulatory compliance aligned with U.S. and international reporting standards.